Fewer than one in 10 people that would benefit from obesity jabs including Wegovy have access to them, warns the World Health Organization as it publishes its initial recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
According to forecasts, over two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be addressed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key barriers to broad availability to the injections that can help people shift considerable body mass, says the organization.
Skinny Jab Supply Crisis
Even in the present best projected case, the supply of these medications might only reach around 100 million people – fewer than 10% of the global need, according to the health organization.
The guideline urges nations and manufacturers to widen availability, through measures like patent sharing.
Exclusive production rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Obesity Jabs Function
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people eat less.
Patients usually see weight reduction in the initial weeks of beginning the regular doses.
Evidence indicates people may put most of the weight back on within a year of discontinuing the drug, because their normal appetite come back.
Being above a healthy weight raises your likelihood for developing health problems, such as diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
